# US 11,857,580 B2 · Lactobacillus having antimicrobial effect on Gardnerella vaginalis and Candida albicans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,857,580 B2
- Document ID: US11857580B2
- Status: Granted
- Kind: B2
- Application number: 16/850,587
- Filed: 2020-04-16
- Published: 2020-11-05
- Granted: 2024-01-02
- Earliest claimed: 2019-05-03
- Assignees: Mediogen Co., Ltd.
- Applicants: Mediogen Co., Ltd.; Nam Soo Paek
- Inventors: Nam-Soo Paek; Chang Ho Kang
- Web page: https://patentgrep.com/patent/US11857580B2

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61P 31/04: Antibacterial agents
- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- C12N 9/2445: {Beta-glucosidase (3.2.1.21)}
- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- A61K 2035/115: {Probiotics}
- C12Y 301/01: Carboxylic ester hydrolases (3.1.1)
- C12Y 301/03002: Acid phosphatase (3.1.3.2)
- C12Y 302/0102: Alpha-glucosidase (3.2.1.20)
- C12Y 302/01021: Beta-glucosidase (3.2.1.21)
- C12Y 302/01031: Beta-glucuronidase (3.2.1.31)
- C12Y 304/11001: Leucyl aminopeptidase (3.4.11.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to a Lactobacillus strain having antimicrobial activity against Gardnerella vaginalis and Candida albicans, a culture medium of the strain, and a cell-free supernatant of the strain, and to an antimicrobial composition containing the same, a pharmaceutical composition for preventing or treating Gardnerella vaginalis infection or Candida albicans infection containing the same, a pharmaceutical composition for prevention or treatment of vaginitis containing the same, a health functional food for prevention or ameliorating of vaginitis containing the same, and a quasi-drug composition for prevention or amelioration of vaginitis containing the same. The Lactobacillus paracasei MG4272 strain in accordance with the present disclosure has excellent antimicrobial activity against Gardnerella vaginalis and Candida albicans, and has excellent acid resistance, bile resistance, autoaggregation ability and epithelial cell adhesion ability and is suitable for probiotics and thus may be used in various ways for the prevention or treatment of Gardnerella vaginalis infection, Candida albicans infection and vaginitis.

## Claims

### Claim 1

A composition comprising a cell-free supernatant of Lactobacillus paracasei MG4272 strain which was deposited under accession number KCTC13822BP,
wherein the Lactobacillus paracasei MG4272 strain is isolated from the human vagina, and
wherein the composition has antifungal activity and antimicrobial activity against Gardnerella vaginalis and Candida albicans.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the Lactobacillus paracasei MG4272 strain is stable at pH 3 to pH 4.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the Lactobacillus paracasei MG4272 strain is stable at pH 7 to pH 9.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the Lactobacillus paracasei MG4272 strain has autoaggregation ability.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the Lactobacillus paracasei MG4272 strain has sugar fermentation activity on D-ribose, D-galactose, D-glucose, D-fructose, D-mannose, L-sorbose, D-mannitol, D-sorbitol, N-acetyl-glucosamine, amygdalin, arbutin, esculin, salicin, D-cellobiose, D-maltose, D-sucrose, inulin, D-melezitose, gentiobiose, D-turanose, D-tagatose, L-arabitol, and gluconate.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the Lactobacillus paracasei MG4272 strain has enzyme activity of Esterase (C4), Esterase lipase (C8), Leucine arylamidase, Valine arylamidase, Acid phosphatase, Naphtol-AS-BI-phosphohydrolase, β-glucuronidase, α-glucosidase, and β-glucosidase.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the Lactobacillus paracasei MG4272 strain is resistant to cefotaxime, cefotetan, kanamycin, streptomycin, nalidixic acid, trimethoprim-sulphamethoxazole, and vancomycin.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the Lactobacillus paracasei MG4272 strain has a cell surface exhibiting hydrophobicity.

### Claim 9 (depends on 1)

A method of treating an animal having a Gardnerella vaginalis infection comprising administering an effective amount of the composition of claim 1.

### Claim 10 (depends on 1)

A method of treating an animal having a Candida albicans infection comprising administering an effective amount of the composition of claim 1.

### Claim 11 (depends on 1)

A method of treating an animal having a vaginitis comprising administering an effective amount of the composition of claim 1.